Market Context — Why This Technology, Why Now

The global cancer burden continues to rise, driving increased adoption of molecular targeted therapies. While highly effective, these treatments present a growing challenge with severe dermatological side effects, creating an urgent demand for advanced supportive care solutions. Healthcare systems worldwide are prioritizing patient quality of life and treatment adherence to maximize therapeutic outcomes and reduce long-term care costs. This technology aligns perfectly with these trends, offering a targeted solution to a critical unmet need in oncology supportive care.

Key Competitive Advantages
01

Demonstrates strong uniqueness with only two prior art documents cited by examiners, positioning it for early market share capture.

02

Provides fundamental therapeutic and preventative effects for hand-foot syndrome caused by molecular targeted drugs, restoring epidermal keratinocyte viability where existing symptomatic treatments are insufficient.

03

Potentially streamlines clinical trials and regulatory approval processes by utilizing known azole antifungals as the active ingredient, compared to developing new chemical entities.

Market Opportunity
Oncology & Cancer Treatment
$3.5B globally (AI est.)
The increasing adoption of molecular targeted therapies drives demand for supportive care that enhances cancer treatment continuity and patient quality of life.
Oncology pharmaceutical companies Cancer treatment centers Medical device manufacturers for supportive care
Dermatology Field
$2B globally (AI est.)
Chemotherapy-induced skin disorders require specialized approaches distinct from general dermatological conditions, increasing the need for targeted therapeutic agents.
Dermatology pharmaceutical companies Specialty dermatological clinics Medical skincare product developers
Pharmaceutical & Healthcare
$35B globally (AI est.)
The global cancer supportive care market is expanding, making this technology attractive for pharmaceutical companies seeking to strengthen their existing drug portfolios.
Large multinational pharmaceutical corporations Biotech firms specializing in oncology Healthcare solution providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent successfully overcame examiner rejections with precise amendments and arguments, demonstrating a robust and clearly defined scope of protection. With only two prior art documents cited, the patent's claims are considered strong and stable, minimizing invalidation risks for potential licensees.

Competitive White Space

Adjacent white space could include developing treatments for other drug-induced dermatological toxicities beyond anticancer agents, or exploring novel drug delivery systems for azole antifungals to enhance localized efficacy and patient compliance.

Economic Impact
~$20M/year estimated healthcare cost reduction (AI est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming 300,000 patients experiencing hand-foot syndrome from molecular targeted therapy in Japan, and an annual reduction of ~$65/patient (AI est.) in healthcare, nursing care, and labor loss costs due to treatment interruption or QOL decline, the estimated annual healthcare cost reduction is ~$20M (AI est.).

Speed to Market
3× faster than in-house development
This technology leverages azole antifungals with established efficacy, potentially significantly shortening development timelines compared to novel compound discovery. Existing pharmacokinetic and safety data could be utilized, allowing for partial omission of preclinical trials and accelerated transition to clinical phases. This could reduce the over 5 years required for in-house R&D to approximately 2 years, enabling faster market entry and revenue generation.
Competitive Positioning

X: Treatment Specificity
Y: Patient QOL Improvement Contribution

Business Models & Applications
💊 Pharmaceutical Development & Sales
Develop and provide pharmaceuticals based on this technology to cancer patients through medical institutions. Establish market dominance through a differentiated mechanism of action.
🤝 Collaborative Research & Licensing
License this technology to pharmaceutical companies for collaborative R&D, manufacturing, and sales. This approach can distribute development risks and aim for earlier market entry.
🧴 Medical Cosmetics & Topical Agent Development
Apply this technology's mechanism to develop and sell specialized medical cosmetics and topical agents for patients undergoing anticancer treatment, thereby opening new market segments.
Adjacent Application Opportunities
Application to Refractory Ulcer Treatment
The mechanism of restoring epidermal keratinocyte viability could be applied to treat refractory wounds like diabetic ulcers and pressure sores. Further research into cell regeneration mechanisms could expand its use in broader skin regenerative medicine, a market projected to reach $10B by 2030.
Sensitive Skin & Barrier Repair Skincare
Applying the mechanism for improving skin barrier function compromised by anticancer therapy, this technology could develop high-performance skincare for sensitive skin suffering from dryness and inflammation. This could create a new market segment, addressing a global sensitive skin market valued at over $15B annually.
Skin Care in Palliative and End-of-Life Care
Beyond anticancer treatment, this technology could prevent and alleviate various skin issues (dryness, itching, pressure sores) in cancer patients receiving palliative care. Developing products that reduce suffering and maintain dignity could significantly improve QOL for millions of patients globally.
Integration Roadmap — Estimated 53-Month Deployment
Technology Evaluation & Formulation Study
Duration: 8 months
Evaluate optimal formulation types (e.g., ointment, cream, oral) for the azole antifungal active ingredient and collect foundational data for preclinical studies.
Preclinical & Clinical Trial Preparation
Duration: 15 months
Conduct safety and efficacy evaluations in animal models while simultaneously preparing for human clinical trials, including protocol development, site selection, and ethics committee applications.
Clinical Trials & Regulatory Approval Application
Duration: 30 months
Execute Phase I/II/III clinical trials and submit a regulatory approval application to the Pharmaceuticals and Medical Devices Agency (PMDA) based on the results. Market launch would commence post-approval.
Technical Feasibility
This technology utilizes azole antifungals, which are widely used pharmaceuticals with extensive safety profiles. As described in Claim 1, a skin disorder treatment agent containing an azole antifungal as the active ingredient could be developed as topical or oral formulations using existing pharmaceutical manufacturing technologies. This approach avoids the need for novel substance synthesis or significant capital investment, leveraging existing drug manufacturing facilities and development expertise, thus presenting relatively low technical hurdles.
Success Scenario
Implementing this technology could enable companies to offer a new treatment option for patients suffering from chemotherapy-induced skin disorders. This is estimated to improve patient treatment adherence by 20% and significantly enhance their quality of life. Consequently, healthcare providers could boost patient satisfaction and contribute to improved treatment outcomes. Furthermore, adopting companies could establish a strong brand image and competitive advantage in the cancer supportive care market through this innovative therapy.
Patent Record
APPLICATION NO.
JP2019-126882
REGISTRATION NO.
7315167
FILING DATE
2019/07/08
GRANT DATE
2023/07/18
EXPIRATION DATE
2039/07/08
PATENT HOLDER
学校法人順天堂
Examination History
2022-04-20
Request for Examination
2023-03-02
Office Action
2023-04-21
Amendment (Voluntary)
2023-04-21
Applicant's Response
2023-06-30
Decision to Grant